Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 13/20 | 0.52 |
| ▸ | FPR3 | P25089 | 1/20 | 0.48 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352302 | 1.00 | CCR1 (0.52) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL3355002 | 0.86 | CCR1 (0.54) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL3355449 | 0.86 | CCR1 (0.54) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL3354789 | 0.85 | CCR1 (0.57) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL3354785 | 0.85 | CCR1 (0.57) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL3354266 | 0.85 | AIMP2 (0.49) | — | |
| SCHEMBL3353758 | 0.84 | CCR1 (0.53) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL3354632 | 0.84 | CCR1 (0.53) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL3353757 | 0.84 | CCR1 (0.53) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL3354640 | 0.84 | CCR1 (0.53) | CCR1FPR3GPR65GPR35PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | claimed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | claimed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | CCR1 1/4885FPR3 59/4885GPR65 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.